Escherichia coli bloodstream infection after transrectal ultrasound-guided prostate biopsy: Implications of fluoroquinolone-resistant sequence type 131 as a major causative pathogen

Clinical Infectious Diseases

Volumn 54, Issue 10, 2012, Pages 1406-1412

  Williamson, Deborah A ^a   Roberts, Sally A ^a   Paterson, David L ^c   Sidjabat, Hanna ^c   Silvey, Anna ^c   Masters, Jonathan ^b   Rice, Michael ^b   Freeman, Joshua T ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b AUCKLAND DISTRICT HEALTH BOARD   (New Zealand)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFALOTIN; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; MEROPENEM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIMENTIN;

ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIAL STRAIN; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; CLONE; CONTROLLED STUDY; ESCHERICHIA COLI; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MOLECULAR TYPING; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; PROSTATE BIOPSY; SEPSIS; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BIOPSY; CHEMOPREVENTION; CLUSTER ANALYSIS; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; MOLECULAR TYPING; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL; YOUNG ADULT;

EID: 84860260505     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis194     Document Type: Article

References (31)

1. Aus G, Abbou CC, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2005; 48:546-51.
2. ACS 2009 American Cancer Society. American Cancer Society recommendations for prostate cancer early detection. Prostate cancer: early detection. 2009. Available at: http://www.cancer.org/Cancer/Prostate-Cancer/MoreInformation/ ProstateCancerEarlyDetection/prostate-cancerearly-detection-acs-recommendations. Accessed 13 September 2011.
3. Loeb S, Ballentine Carter H, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011; 186:1830-4.
4. Nam RK, Saskin R, Lee Y, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2010; 183:963-8.
5. Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schrder FH. Complication rates and risk factors of 5802 transrectal ultrasoundguided sextant biopsies of the prostate within a population-based screening program. Urology 2002; 60:826-30.
6. Tal R, Livne PM, Lask DM, Baniel J. Empirical management of urinary tract infections complicating transrectal ultrasound guided prostate biopsy. J Urol 2003; 169:1762-5.
7. Aron M, Rajeev TP, Gupta NP. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int 2000; 85:682-5.
8. Zani EL, Clark OA, Rodrigues Netto N Jr. Antibiotic prophylaxis for transrectal prostate biopsy. Cochrane Database Syst Rev 2011; (5): CD006576.
9. Shandera KC, Thibault GP, Deshon GE Jr. Variability in patient preparation for prostate biopsy among American urologists. Urology 1998; 52:644-6.
10. Wolf JS Jr, Bennett CJ, Dmochowski RR, Hollenbeck BK, Pearle MS, Schaeffer AJ. Urologic Surgery Antimicrobial Prophylaxis Best Practice Policy Panel. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol 2008; 179:1379-90.
11. Drusano GL, Preston SL, Van Guilder M, et al. A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin. Antimicrob Agents Chemother 2000; 44:2046-51.
12. Zaytoun OM, Vargo EH, Rajan R, Berglund R, Gordon S, Jones JS. Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment. Urology 2011; 77:1035-41.
13. Feliciano J, Teper E, Ferrandino M, et al. The incidence of fluoroquinolone resistant infections after prostate biopsy-are fluoroquinolones still effective prophylaxis? J Urol 2008; 179:952-5.
14. Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 2011; 66:1-14.
15. Peirano G, Pitout JD. Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4. Int J Antimicrob Agents 2010; 35:316-21.
16. Johnson JR, Stell AL. Extended virulence genotypes of Escherichia coli strains from patients with urosepsis in relation to phylogeny and host compromise. J Infect Dis 2000; 181:261-72.
17. Johnson J, Johnston B, Clabots C, et al. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis 2010; 51:286-94.
18. Peirano G, Costello M, Pitout JD. Molecular characteristics of extended-spectrum beta-lactamase-producing Escherichia coli from the Chicago area: high prevalence of ST131 producing CTX-M-15 in community hospitals. Int J Antimicrob Agents 2010; 36:19-23.
19. Leflon-Guibout V, Blanco J, Amaqdouf K, Mora A, Guize L, Nicolas-Chanoine MH. Absence of CTX-M enzymes but high prevalence of clones, including clone ST131, among fecal Escherichia coli isolates from healthy subjects living in the area of Paris, France. J Clin Microbiol 2008; 46:3900-5.
20. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40:373-83.
21. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 15th informational supplement. CLSI document M100-S20. Wayne, PA: Clinical and Laboratory Standards Institute, 2010.
22. Clermont O, Bonacorsi S, Bingen E. Rapid and simple determination of the Escherichia coli phylogenetic group. Appl Environ Microbiol 2000; 66:4555-8.
23. Pitout JD, Campbell L, Church DL, Wang PW, Guttman DS, Gregson DB. Using a commercial DiversiLab semiautomated repetitive sequence-based PCR typing technique for identification of Escherichia coli clone ST131 producing CTX-M-15 J. Clin Microbiol 2009; 47:1212-15.
24. Sannes MR, Kuskowski MA, Owens K, Gajewski A, Johnson JR. Virulence factor profiles and phylogenetic background of Escherichia coli isolates from veterans with bacteremia and uninfected control subjects. J Infect Dis 2004; 190:2121-8.
25. Young JL, Liss MA, Szabo RJ. Sepsis due to fluoroquinolone-resistant Escherichia coli after transrectal ultrasound-guided prostate needle biopsy. Urology 2009; 74:332-8.
26. Hadway P, Barrett LK, Waghorn DJ, et al. Urosepsis and bacteraemia caused by antibiotic-resistant organisms after transrectal ultrasonographyguided prostate biopsy. BJU Int 2009; 104:1556-8.
27. Pitout JD, Campbell L, Church DL, Gregson DB, Laupland KB. Molecular characteristics of travel-related extended-spectrum-betalactamase-producing Escherichia coli isolates from the Calgary Health Region. Antimicrob Agents Chemother 2009; 53:2539-43.
28. Johnson JR, Johnston B, Clabots C, et al. Escherichia coli sequence type ST131 as an emerging fluoroquinolone-resistant uropathogen among renal transplant recipients. Antimicrob Agents Chemother 2010; 54: 546-50.
29. Peirano G, Schreckenberger PC, Pitout JD. Characteristics of NDM-1-producing Escherichia coli isolates that belong to the successful and virulent clone ST131. Antimicrob Agents Chemother 2011; 55:2986-8.
30. Liss MA, Peeples AN, Peterson EM. Detection of fluoroquinoloneresistant organisms from rectal swabs by use of selective media prior to a transrectal prostate biopsy. J Clin Microbiol 2011; 49:1116-18.
31. Zaytoun OM, Anil T, Moussa AS, Jianbo L, Fareed K, Jones JS. Morbidity of prostate biopsy after simplified versus complex preparation protocols: assessment of risk factors. Urology 2011; 77:910-15.